Skip to content
Illustration by Noah Hickey/The Dispatch (Photos by Kevin Dietsch and Anna Moneymaker/Getty Images).
Grayson Logue /

Vaccine Development and the Costs of Uncertainty

The FDA’s flip-flop on a new flu shot prompts fresh concern in the pharmaceutical industry.
Illustration by Noah Hickey/The Dispatch (Photos by Kevin Dietsch and Anna Moneymaker/Getty Images).

The U.S. Food and Drug Administration shocked the vaccine industry earlier this month by refusing to evaluate Moderna’s new mRNA flu vaccine for approval. The biotech giant had spent more than a billion dollars testing the new shot, which had shown promising results compared to a standard flu shot in a 40,000-person clinical trial.

Want to see more of The Dispatch in Google search?

Add Us as a Preferred Source

Grayson Logue is a staff writer for The Dispatch and is based in Philadelphia, Pennsylvania. Prior to joining the company in 2023, he worked in political risk consulting, helping advise Fortune 50 companies. He was also an assistant editor at Providence Magazine and is a graduate student at the University of Edinburgh, pursuing a Master’s degree in history. When Grayson is not writing pieces for the website, he is probably working hard to reduce the number of balls he loses on the golf course.

More We Think You’d Like

Loading